The ZEISS MyoCare portfolio uses an optical strategy backed by scientific evidence from 18 peer-reviewed publications to correct refractive errors and slow myopia progression. From private practices to university hospitals, eye care professionals in over 100 countries count on MyoCare® and MyoCare® S lenses for their young patients.
A harder design variant with a smaller clear zone and stronger mean addition power. Recommended as the starter lens for children of all ages.
These lenses feature a larger clear zone and softer mean addition power. Recommended for children who have difficulty adapting to ZEISS MyoCare lenses.
of children adapted to their ZEISS MyoCare or MyoCare S lenses within three days.1
of all participants subjectively rated vision with ZEISS MyoCare lenses as very good for far distances.1
of wearers rated vision with ZEISS MyoCare or MyoCare S lenses as very good for near distances.1
The 24-month results of the randomised multi clinical trial in China show a significant difference in axial length change and spherical equivalent refraction error change between the untreated group wearing single vision lenses and the treatment group wearing ZEISS MyoCare lens designs.1
Clinically proven across two continents
Results confirmed in both Asian and European multicentre randomised controlled trials.
MyoCare® lenses proved effective in slowing myopia progression in extensive clinical testing conducted on two different continents: They can reduce the occurrence of fast myopia progression by up to 3.5 times.2
Two different multicentre clinical trials in China (NCT 05288335) and Europe (NCT 05919654) demonstrated that ZEISS MyoCare lens designs can help slow myopia progression compared to ZEISS single vision lenses. The rate of progression among children wearing MyoCare® and MyoCare® S lenses was significantly reduced in the first and second years of the clinical trial.
The 24-month results of the randomised multi clinical trial in China show a significant difference in axial length change and spherical equivalent refraction error change between the untreated group wearing single vision lenses and the treatment group wearing ZEISS MyoCare lens designs.1
Clinically proven across two continents
Results confirmed in both Asian and European multicentre randomised controlled trials.
Share your inquiry with us. How can we assist you?
Not all products, services or offers are approved or offered in every market and approved labelling and instructions may vary from one country to another. For country specific product information, see the appropriate country website.
